Migraine is a chronic, recurrent disorder affecting an estimated 37 million Americans. Migraine is marked by recurring moderate to severe headache with throbbing pain that usually lasts from 4-72 hours, typically unilateral in location, is often accompanied by nausea, vomiting, and sensitivity to light or sound.

Around 12% of adults have episodic migraine (occurring less than 15 days per month). These individuals experience impaired health-related quality of life and considerable disability during those days.

The purpose of this research study is to examine the safety, tolerability, and efficacy of an investigational nasal spray for the treatment of episodic migraine headaches.

Study related care is provided to participants at no cost. Compensation is available up $375 for time and travel for those who qualify.


  • Adults 18-65 years old
  • History of migraines (with or without aura) for more than one year with age of onset under 50
  • 4-14 moderate to severe migraine attacks per month in each of the last two months
  • *Please note, other conditions may apply